Spots Global Cancer Trial Database for childhood diffuse large cell lymphoma
Every month we try and update this database with for childhood diffuse large cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma | NCT00983944 | Lymphoma | bleomycin sulfa... rituximab EPOCH regimen cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul... | 10 Years - | Ohio State University Comprehensive Cancer Center | |
| Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | NCT00058461 | B-cell Childhoo... Childhood Burki... Childhood Diffu... Childhood Immun... L3 Childhood Ac... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | ifosfamide etoposide rituximab carboplatin filgrastim methotrexate cytarabine laboratory biom... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | NCT00058461 | B-cell Childhoo... Childhood Burki... Childhood Diffu... Childhood Immun... L3 Childhood Ac... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | ifosfamide etoposide rituximab carboplatin filgrastim methotrexate cytarabine laboratory biom... | - 21 Years | National Cancer Institute (NCI) | |
| Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | NCT00057811 | Childhood Burki... Childhood Diffu... Childhood Immun... Stage I Childho... Stage I Childho... Stage II Childh... Stage II Childh... Stage III Child... Stage III Child... Stage IV Childh... Stage IV Childh... Untreated Child... | doxorubicin hyd... cyclophosphamid... methotrexate rasburicase leucovorin calc... prednisone methylprednisol... filgrastim rituximab cytarabine etoposide vincristine sul... hydrocortisone ... laboratory biom... | 1 Year - 29 Years | Children's Oncology Group | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma | NCT00983944 | Lymphoma | bleomycin sulfa... rituximab EPOCH regimen cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul... | 10 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
